Search results for "amisulpride"

showing 9 items of 19 documents

Erste Erfahrungen mit Amisulprid, einem in Deutschland neuen, atypischen Neuroleptikum in der Behandlung von Jugendlichen mit psychischen Erkrankungen

2001

Zusammenfassung: Fragestellung: Neben den klassischen Neuroleptika finden bei Jugendlichen zunehmend atypische Neuroleptika zur Behandlung schizophrener und schizoaffektiver Psychosen Verwendung. Seit Beginn des Jahres 1999 ist in Deutschland in der Behandlung akuter schizophrener Psychosen ein neues, offensichtlich wirkungsvolles Neuroleptikum aus der Gruppe der Benzamide verfügbar: Amisulprid. Erste Erfahrungen mit der Anwendung von Amisulprid werden berichtet. Methode: Zehn gut dokumentierte Behandlungsverläufe bei Jugendlichen unter Behandlung mit Amisulprid werden hinsichtlich Effektivität, unerwünschter Wirkungen und Dosierung berichtet. Ergebnisse: Erste Erfahrungen im Einsatz von Am…

Drugmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectmedicine.medical_treatmentAtypical neurolepticGeneral MedicineTreatment resultsControlled studiesmedicine.diseasePsychiatry and Mental healthClinical PsychologySchizophreniaPediatrics Perinatology and Child HealthmedicineAmisulprideAntipsychoticbusinessPsychiatrymedia_commonmedicine.drugZeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie
researchProduct

Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.

2004

Abstract The pharmacokinetics of antipsychotic drugs has become an integral part in understanding their pharmacodynamic activity and clinical effects. In addition to metabolism aspects, carrier-mediated transport, particularly secretion by ABC transporters, has been discussed as potentially relevant for this group of therapeutics. In this study, the psychoactive compounds perphenazine, flupentixol, domperidone, desmethyl clozapine, haloperidol, fluphenazine, fluvoxamine, olanzapine, levome-promazine, perazine, desmethyl perazine, clozapine, quetiapine and amisulpride were characterized in terms of P-glycoprotein (P-gp) affinity and transport. Experimental methods involved a radioligand disp…

FluphenazineMalePerphenazineATP Binding Cassette Transporter Subfamily BPharmaceutical SciencePharmacologySubstrate Specificitychemistry.chemical_compoundPharmacokineticsmedicineFluphenazineAnimalsHumansDrug InteractionsTissue DistributionAmisulprideClozapinePharmacologyBrainPerazineFlupentixolRatschemistryCyclosporineAmisulprideCaco-2 CellsSulpirideImmunosuppressive Agentsmedicine.drugTalinololAntipsychotic AgentsThe Journal of pharmacy and pharmacology
researchProduct

Rotarod impairment: catalepsy-like screening test for antipsychotic side effects.

2009

Extrapyramidal motoric symptoms are casual side effects under antipsychotic medication. New generation antipsychotics are expected to have a reduced risk due to different receptor affinities. Here, haloperidol and the new generation antipsychotics, risperidone, amisulpride, and aripiprazole, were examined with both catalepsy test and rotarod performance test to screen for their usability in mice. Mice treated with haloperidol, risperidone, and aripiprazole showed dose and time-dependent impairment. Amisulpride-treated mice showed no signs of catalepsy. Catalepsy test and rotarod performance test were useful methods to detect side effects of both generation antipsychotics. Catalepsy test pro…

Malemedicine.medical_specialtyTime FactorsScreening testmedicine.medical_treatmentStatistics as TopicDrug Evaluation PreclinicalCatalepsyPharmacologyMotor ActivityRotarod performance testMiceBasal Ganglia DiseasesmedicineHaloperidolAnimalsAmisulprideAntipsychoticPsychiatryFreezing Reaction CatalepticRisperidoneDose-Response Relationship DrugGeneral NeuroscienceGeneral Medicinemedicine.diseaseDisease Models AnimalRotarod Performance TestAripiprazolePsychologymedicine.drugAntipsychotic AgentsThe International journal of neuroscience
researchProduct

Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs

2009

Studies conducted to obtain drug authorization are often of short duration and based on small sample sizes in selected populations. Policies on drug safety rely on the validity of the methods used to achieve rapid and effective communication of new information. No formal evaluation has ever been made of the Spanish communications system, although indirect data have raised questions about its effectiveness.To evaluate the impact of two safety warnings issued by the Spanish Drug Agency, and of a later prior authorization requirement involving the use of atypical antipsychotic drugs in the elderly.The study was based on a time-series analysis constructed with data corresponding to monthly invo…

Olanzapinemedicine.medical_specialtymedicine.drug_classAtypical antipsychoticToxicologyCommunications systemInterrupted Time Series AnalysisBenzodiazepinesmedicineHumansPharmacology (medical)ZiprasidoneAmisulpridePractice Patterns Physicians'Medical prescriptionPsychiatryAgedPharmacologyRisperidoneDose-Response Relationship DrugInformation Disseminationbusiness.industryRisperidonemedicine.diseaseOlanzapineSpainDrug and Narcotic ControlDementiaMedical emergencybusinessAntipsychotic Agentsmedicine.drugDrug Safety
researchProduct

Therapeutic monitoring of new antipsychotic drugs.

2004

Typical antipsychotic drugs qualify for therapeutic drug monitoring (TDM) primarily for the following reasons: control of compliance and avoidance of extrapyramidal side effects by keeping chronic exposure to minimal effective blood levels. For the atypical antipsychotic clozapine, drug safety is another reason to use TDM. With regard to the new antipsychotics risperidone, olanzapine, quetiapine, amisulpride, ziprasidone, and aripiprazole, which have been introduced in the clinic during the last few years, the rationale to use TDM is a matter of debate. Positron emission tomography (PET), which enables measurement of the occupancy of dopamine D2 receptors, revealed that receptor occupancy c…

PharmacologyOlanzapinemedicine.diagnostic_testDose-Response Relationship Drugmedicine.drug_classbusiness.industryReceptors Dopamine D2medicine.medical_treatmentAtypical antipsychoticPharmacologyTypical antipsychoticStructure-Activity RelationshipTherapeutic drug monitoringmedicineQuetiapineHumansPharmacology (medical)ZiprasidoneAmisulprideDrug MonitoringAntipsychoticbusinessmedicine.drugAntipsychotic AgentsTherapeutic drug monitoring
researchProduct

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D …

1998

The benzamide amisulpride (ASP) is a selective D2-like dopamine antagonist, while flupentixol (FPX), a thioxanthene, blocks D2-like, D1-like and 5-HT2 receptors. To evaluate efficacy and safety of ASP and to investigate the importance of an additional D1-like antagonism for antipsychotic effects and extrapyramidal tolerability, a randomized double-blind multi-center study versus FPX as reference drug was performed for 6 weeks in 132 patients suffering from acute schizophrenia (DSM-III-R) with predominant positive symptomatology. Doses were initially fixed (ASP: 1000 mg/day; FPX: 25 mg/day) but could be reduced by 40% in case of side effects (mean daily doses: ASP: 956 mg; FPX: 22.6 mg). Int…

Pharmacologymedicine.medical_treatmentAntagonistDopamine antagonistPharmacologyFlupentixolBarnes Akathisia ScaleTolerabilitymedicineAmisulprideAntipsychoticAdverse effectPsychologymedicine.drugPsychopharmacology
researchProduct

How Does the Benzamide Antipsychotic Amisulpride get into the Brain?—An In Vitro Approach Comparing Amisulpride with Clozapine

2003

This study evaluated the disposition of the two atypical antipsychotics, amisulpride (AMS) and clozapine (CLZ), and its main metabolite N-desmethylclozapine (DCLZ), to their target structures in the central nervous system by applying an in vitro blood-brain barrier and blood-cerebrospinal fluid (CSF) barrier based on monolayers of porcine brain microvessel endothelial cells (PMEC) or porcine choroid plexus epithelial cells (PCEC). Permeation studies through PMEC- and PCEC-monolayers were conducted for 60 min at drug concentrations of 1, 5, 10, and 30 muM applied to the donor compartment. PMEC were almost impermeable for AMS (permeation coefficient, P1 x 10(-7) cm/s) in the resorptive direct…

SwineMetabolitePharmacologyBlood–brain barrierchemistry.chemical_compoundmedicineAnimalsHumansAmisulprideBenzamideClozapineClozapinePharmacologyDose-Response Relationship DrugAntagonistBrainPermeationPsychiatry and Mental healthmedicine.anatomical_structurechemistryBenzamidesChoroid plexusAmisulprideCaco-2 CellsSulpirideAntipsychotic Agentsmedicine.drugNeuropsychopharmacology
researchProduct

Ankk1 Loss of Function Disrupts Dopaminergic Pathways in Zebrafish

2022

Ankyrin repeat and kinase domain containing 1 (ANKK1) is a member of the receptor-interacting protein serine/threonine kinase family, known to be involved in cell proliferation, differentiation and activation of transcription factors. Genetic variation within the ANKK1 locus is suggested to play a role in vulnerability to addictions. However, ANKK1 mechanism of action is still poorly understood. It has been suggested that ANKK1 may affect the development and/or functioning of dopaminergic pathways. To test this hypothesis, we generated a CRISPR-Cas9 loss of function ankk1 zebrafish line causing a 27 bp insertion that disrupts the ankk1 sequence introducing an early stop codon. We found that…

amisulpridedopaminergic systemGeneral NeuroscienceDRD2NeurociènciesNeurosciences. Biological psychiatry. NeuropsychiatryDopaminaPeixosaddictionapomorphineANKK1RC321-571Frontiers in Neuroscience
researchProduct

Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy

2009

Evidence has been given that antipsychotic effects of dopamine receptor antagonists are associated with 60 and 80% striatal dopamine D2 and D3 receptor occupancy. Receptor occupancy correlates well with concentrations of the antipsychotic drugs in serum or plasma, much better than the dose. The latter is consistent with weak correlations between antipsychotic dose and serum concentrations and explained by the high interindividual variabilities in drug metabolism. Using positron emission tomography (PET) for in vivo determination of dopamine receptor occupancy in conjunction with drug concentration measurements “therapeutic windows” could be calculated for the atypical antipsychotic drugs am…

medicine.diagnostic_testbusiness.industrymedicine.drug_classAtypical antipsychoticPharmacologyPsychiatry and Mental healthDopamine receptorDopamine receptor D3Therapeutic drug monitoringAnesthesiaMedicineZiprasidoneAripiprazoleAmisulpridebusinessClozapinemedicine.drugEuropean Psychiatry
researchProduct